AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder Transcript
Source: SeekingAlpha
2026-02-27 06:57:51 ET
AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder February 26, 2026 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder Transcript
ATAI Life Sciences N.V.
NASDAQ: ATAI
ATAI Trading
11.62% G/L:
$4.18 Last:
5,733,753 Volume:
$3.84 Open:
ATAI Latest News
March 10, 2026 06:00:00 am
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
March 09, 2026 10:50:00 am
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
ATAI Stock Data
$1,443,705,400
301,295,593
0.1%
45
N/A
Biotechnology & Life Sciences
Healthcare
DE
Amstelveen
